{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T20:21:48Z","timestamp":1787862108701,"version":"build-2784847793"},"reference-count":145,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.clml.2026.05.012","type":"journal-article","created":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T23:56:07Z","timestamp":1780617367000},"page":"e1080-e1092","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Second Primary Malignancies in Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma: A Comprehensive Review"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4050-6690","authenticated-orcid":false,"given":"Julian J.","family":"Guetta-Weiss","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle M.","family":"Brander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.clml.2026.05.012_bib0001","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2016.105","article-title":"Improved survival for patients diagnosed with chronic lymphocytic leukemia in the era of chemo-immunotherapy: a Danish population-based study of 10455 patients","volume":"6","author":"da Cunha-Bang","year":"2016","journal-title":"Blood Cancer J"},{"issue":"10","key":"10.1016\/j.clml.2026.05.012_bib0002","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/s41408-021-00556-7","article-title":"Survival of patients with chronic lymphocytic leukemia before and after the introduction of chemoimmunotherapy in Germany","volume":"11","author":"Kaj\u00fcter","year":"2021","journal-title":"Blood Cancer J"},{"issue":"10","key":"10.1016\/j.clml.2026.05.012_bib0003","doi-asserted-by":"crossref","first-page":"2501","DOI":"10.1007\/s00277-021-04600-1","article-title":"Survival trends in chronic lymphocytic leukemia across treatment eras: US SEER database analysis (1985\u20132017)","volume":"100","author":"Alrawashdh","year":"2021","journal-title":"Ann Hematol"},{"issue":"5","key":"10.1016\/j.clml.2026.05.012_bib0004","first-page":"409","article-title":"Cancer treatment and survivorship statistics, 2022","volume":"72","author":"Miller","year":"2022","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clml.2026.05.012_bib0005","article-title":"Chronic lymphocytic leukaemia","volume":"3","author":"Kipps","year":"2017","journal-title":"Nat Rev Dis Primers"},{"issue":"11","key":"10.1016\/j.clml.2026.05.012_bib0006","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1002\/ajh.25595","article-title":"Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment","volume":"94","author":"Hallek","year":"2019","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2026.05.012_bib0007","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.840616","article-title":"Trends in disease burden of chronic lymphocytic leukemia at the global, regional, and national levels from 1990 to 2019, and projections until 2030: a population-based epidemiologic study","volume":"12","author":"Ou","year":"2022","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.clml.2026.05.012_bib0008","first-page":"7","article-title":"Cancer statistics, 2018","volume":"68","author":"Siegel","year":"2018","journal-title":"CA Cancer J Clin"},{"issue":"21","key":"10.1016\/j.clml.2026.05.012_bib0009","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1182\/blood.2019003453","article-title":"International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia","volume":"135","author":"Condoluci","year":"2020","journal-title":"Blood"},{"issue":"25","key":"10.1016\/j.clml.2026.05.012_bib0010","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood-2017-09-806398","article-title":"iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL","volume":"131","author":"Hallek","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.05.012_bib0011","unstructured":"Network N.C.C. Chronic lymphocytic leukemia\/small lymphocytic lymphoma (Version 1.2025). Available at: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/cll.pdf Accessed: October 12, 2024."},{"issue":"4","key":"10.1016\/j.clml.2026.05.012_bib0012","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41408-022-00669-7","article-title":"Long-term trends in the loss in expectation of life after a diagnosis of chronic lymphocytic leukemia: a population-based study in the Netherlands, 1989-2018","volume":"12","author":"van der Straten","year":"2022","journal-title":"Blood Cancer J"},{"issue":"1","key":"10.1016\/j.clml.2026.05.012_bib0013","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/jha2.368","article-title":"Conditional relative survival among patients with chronic lymphocytic leukaemia: a population-based study in the Netherlands","volume":"3","author":"van der Straten","year":"2022","journal-title":"EJHaem"},{"issue":"9","key":"10.1016\/j.clml.2026.05.012_bib0014","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1038\/s41375-021-01156-x","article-title":"Mapping comorbidity in chronic lymphocytic leukemia: impact of individual comorbidities on treatment, mortality, and causes of death","volume":"35","author":"Rotbain","year":"2021","journal-title":"Leukemia"},{"issue":"3","key":"10.1016\/j.clml.2026.05.012_bib0015","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1111\/bjh.14785","article-title":"Relationship between co-morbidities at diagnosis, survival and ultimate cause of death in patients with chronic lymphocytic leukaemia (CLL): a prospective cohort study","volume":"178","author":"Strati","year":"2017","journal-title":"Br J Haematol"},{"issue":"8","key":"10.1016\/j.clml.2026.05.012_bib0016","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/s41408-021-00532-1","article-title":"Cause of death in patients with newly diagnosed chronic lymphocytic leukemia (CLL) stratified by the CLL-International Prognostic Index","volume":"11","author":"Wang","year":"2021","journal-title":"Blood Cancer J"},{"issue":"5","key":"10.1016\/j.clml.2026.05.012_bib0017","first-page":"741","article-title":"The incidence of multiple primary cancers. I. Development of further cancers in patients with lymphomas, leukemias, and myeloma","volume":"38","author":"Berg","year":"1967","journal-title":"J Natl Cancer Inst"},{"issue":"7","key":"10.1016\/j.clml.2026.05.012_bib0018","first-page":"177","article-title":"Skin carcinomata and chronic lymphatic leukaemia\u2013an association","volume":"67","author":"Moriarty","year":"1974","journal-title":"J Ir Med Assoc"},{"issue":"3","key":"10.1016\/j.clml.2026.05.012_bib0019","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1001\/jama.1975.03250030023012","article-title":"Subsequent neoplasia in chronic lymphocytic leukemia","volume":"232","author":"Manusow","year":"1975","journal-title":"Jama"},{"issue":"9","key":"10.1016\/j.clml.2026.05.012_bib0020","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/nrc.2017.60","article-title":"Therapy-related myeloid neoplasms: when genetics and environment collide","volume":"17","author":"McNerney","year":"2017","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1016\/j.clml.2026.05.012_bib0021","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/bjh.18129","article-title":"Clonal haematopoiesis as a risk factor for therapy-related myeloid neoplasms in patients with chronic lymphocytic leukaemia treated with chemo-(immuno)therapy","volume":"198","author":"Voso","year":"2022","journal-title":"Br J Haematol"},{"issue":"6","key":"10.1016\/j.clml.2026.05.012_bib0022","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1097\/CCO.0b013e32834bcc2a","article-title":"Therapy-related myeloid neoplasms","volume":"23","author":"Leone","year":"2011","journal-title":"Curr Opin Oncol"},{"key":"10.1016\/j.clml.2026.05.012_bib0023","doi-asserted-by":"crossref","first-page":"5909","DOI":"10.2147\/OTT.S101333","article-title":"Therapy-related myeloid neoplasms: clinical perspectives","volume":"11","author":"Fianchi","year":"2018","journal-title":"Onco Targets Ther"},{"issue":"6","key":"10.1016\/j.clml.2026.05.012_bib0024","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000716","article-title":"Therapy-related myeloid neoplasms in patients with chronic lymphocytic leukemia who received FCR\/FC as frontline Therapy","volume":"6","author":"Laribi","year":"2022","journal-title":"HemaSphere"},{"issue":"9","key":"10.1016\/j.clml.2026.05.012_bib0025","doi-asserted-by":"crossref","first-page":"e301","DOI":"10.1016\/j.clml.2024.05.009","volume":"24","author":"Ghosh","year":"2024","journal-title":"Clin Lymphoma Myeloma"},{"issue":"1","key":"10.1016\/j.clml.2026.05.012_bib0026","doi-asserted-by":"crossref","first-page":"63","DOI":"10.7326\/0003-4819-119-1-199307010-00011","article-title":"Genetic relatedness of lymphoid malignancies. Transformation of chronic lymphocytic leukemia as a model","volume":"119","author":"Foon","year":"1993","journal-title":"Ann Intern Med"},{"issue":"9","key":"10.1016\/j.clml.2026.05.012_bib0027","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.clml.2017.06.028","article-title":"Risk of second primary malignancies in patients with follicular lymphoma: a United States population-based study","volume":"17","author":"Giri","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"33","key":"10.1016\/j.clml.2026.05.012_bib0028","doi-asserted-by":"crossref","first-page":"4935","DOI":"10.1200\/JCO.2010.29.1112","article-title":"Second malignancy risks after non-Hodgkin's lymphoma and chronic lymphocytic leukemia: differences by lymphoma subtype","volume":"28","author":"Morton","year":"2010","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clml.2026.05.012_bib0029","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1093\/jnci\/djk030","article-title":"Second cancer incidence and cause-specific mortality among 3104 patients with hairy cell leukemia: a population-based study","volume":"99","author":"Hisada","year":"2007","journal-title":"J Natl Cancer Inst"},{"issue":"2","key":"10.1016\/j.clml.2026.05.012_bib0030","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1111\/bjh.15777","article-title":"Second primary cancers in patients with acute lymphoblastic, chronic lymphocytic and hairy cell leukaemia","volume":"185","author":"Zheng","year":"2019","journal-title":"Br J Haematol"},{"issue":"3","key":"10.1016\/j.clml.2026.05.012_bib0031","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1111\/bjh.12908","article-title":"Long-term follow-up and second malignancies in 487 patients with hairy cell leukaemia","volume":"166","author":"Cornet","year":"2014","journal-title":"Br J Haematol"},{"issue":"7","key":"10.1016\/j.clml.2026.05.012_bib0032","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1054\/bjoc.2001.1998","article-title":"Second primary neoplasms among 53 159 haematolymphoproliferative malignancy patients in Sweden, 1958-1996: a search for common mechanisms","volume":"85","author":"Dong","year":"2001","journal-title":"Br J Cancer"},{"issue":"12","key":"10.1016\/j.clml.2026.05.012_bib0033","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1038\/s41375-020-0987-6","article-title":"Second cancer incidence in CLL patients receiving BTK inhibitors","volume":"34","author":"Bond","year":"2020","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.clml.2026.05.012_bib0034","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/ijc.22672","article-title":"Risk of second cancer after chronic lymphocytic leukemia","volume":"121","author":"Schollkopf","year":"2007","journal-title":"Int J Cancer"},{"issue":"7","key":"10.1016\/j.clml.2026.05.012_bib0035","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1038\/bjc.2011.313","article-title":"Second cancer incidence and cancer mortality among chronic lymphocytic leukaemia patients: a population-based study","volume":"105","author":"Royle","year":"2011","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1016\/j.clml.2026.05.012_bib0036","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1182\/blood.V98.6.1979","article-title":"Solid tumors after chronic lymphocytic leukemia","volume":"98","author":"Hisada","year":"2001","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.clml.2026.05.012_bib0037","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41408-019-0237-1","article-title":"Trends in the risk of second primary malignancies among survivors of chronic lymphocytic leukemia","volume":"9","author":"Kumar","year":"2019","journal-title":"Blood Cancer J"},{"issue":"6993","key":"10.1016\/j.clml.2026.05.012_bib0038","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1136\/bmj.310.6993.1491","article-title":"Evidence of an association between non-Hodgkin's lymphoma and skin cancer","volume":"310","author":"Adami","year":"1995","journal-title":"Bmj"},{"issue":"11","key":"10.1016\/j.clml.2026.05.012_bib0039","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1038\/bjc.1996.642","article-title":"Non-Hodgkin's lymphomas, chronic lymphocytic leukaemias and skin cancers","volume":"74","author":"Levi","year":"1996","journal-title":"Br J Cancer"},{"issue":"6","key":"10.1016\/j.clml.2026.05.012_bib0040","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.jaad.2005.08.055","article-title":"Increased metastasis and mortality from cutaneous squamous cell carcinoma in patients with chronic lymphocytic leukemia","volume":"53","author":"Mehrany","year":"2005","journal-title":"J Am Acad Dermatol"},{"issue":"8","key":"10.1016\/j.clml.2026.05.012_bib0041","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1001\/archderm.140.8.985","article-title":"High recurrence rates of basal cell carcinoma after Mohs surgery in patients with chronic lymphocytic leukemia","volume":"140","author":"Mehrany","year":"2004","journal-title":"Arch Dermatol"},{"issue":"1","key":"10.1016\/j.clml.2026.05.012_bib0042","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1097\/00042728-200501000-00008","article-title":"High recurrence rates of squamous cell carcinoma after Mohs' surgery in patients with chronic lymphocytic leukemia","volume":"31","author":"Mehrany","year":"2005","journal-title":"Dermatol Surg"},{"issue":"1","key":"10.1016\/j.clml.2026.05.012_bib0043","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1038\/s41408-023-00784-z","article-title":"Risk of second primary malignancies in patients with chronic lymphocytic leukemia: a population-based study in the Netherlands, 1989-2019","volume":"13","author":"van der Straten","year":"2023","journal-title":"Blood Cancer J"},{"issue":"6","key":"10.1016\/j.clml.2026.05.012_bib0044","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.31557\/APJCP.2023.24.6.1971","article-title":"Evaluation of second primary cancer risk among chronic lymphocytic leukemia patients: multicenter study","volume":"24","author":"Sayin","year":"2023","journal-title":"Asian Pac J Cancer Prev"},{"issue":"6","key":"10.1016\/j.clml.2026.05.012_bib0045","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1093\/annonc\/mdw072","article-title":"Incidence and prognostic impact of other cancers in a population of long-term survivors of chronic lymphocytic leukemia","volume":"27","author":"Falchi","year":"2016","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.clml.2026.05.012_bib0046","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1080\/10428190310001612939","article-title":"Veterans with chronic lymphocytic leukemia\/small lymphocytic lymphoma (CLL\/SLL) have a markedly increased rate of second malignancy, which is the most common cause of death","volume":"45","author":"Kyasa","year":"2004","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.clml.2026.05.012_bib0047","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1002\/jha2.366","article-title":"Second primary malignancies in chronic lymphocytic leukaemia: skin, solid organ, haematological and Richter's syndrome","volume":"3","author":"Shen","year":"2022","journal-title":"EJHaem"},{"issue":"6","key":"10.1016\/j.clml.2026.05.012_bib0048","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.3109\/10428194.2014.957203","article-title":"Second cancers in patients with chronic lymphocytic leukemia who received frontline fludarabine, cyclophosphamide and rituximab therapy: distribution and clinical outcomes","volume":"56","author":"Benjamini","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2026.05.012_bib0049","article-title":"Other malignancies in the history of CLL: an international multicenter study conducted by ERIC, the European Research Initiative on CLL, in HARMONY","volume":"65","author":"Chatzikonstantinou","year":"2023","journal-title":"eClin Med"},{"issue":"7","key":"10.1016\/j.clml.2026.05.012_bib0050","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1200\/JCO.2012.43.4449","article-title":"Overall and cancer-specific survival of patients with breast, colon, kidney, and lung cancers with and without chronic lymphocytic leukemia: a SEER population-based study","volume":"31","author":"Solomon","year":"2013","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.clml.2026.05.012_bib0051","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1111\/j.1524-4725.2009.01447.x","article-title":"Effects of chronic lymphocytic leukemia on the development and progression of malignant melanoma","volume":"36","author":"Brewer","year":"2010","journal-title":"Dermatol Surg"},{"issue":"8","key":"10.1016\/j.clml.2026.05.012_bib0052","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1200\/JCO.2011.34.9605","article-title":"Chronic lymphocytic leukemia is associated with decreased survival of patients with malignant melanoma and Merkel cell carcinoma in a SEER population-based study","volume":"30","author":"Brewer","year":"2012","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.clml.2026.05.012_bib0053","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1056\/NEJMoa2409804","article-title":"Fixed-duration acalabrutinib combinations in untreated chronic lymphocytic leukemia","volume":"392","author":"Brown","year":"2025","journal-title":"N Engl J Med"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.05.012_bib0054","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1182\/blood-2025-2129","volume":"146","author":"Tam","year":"2025","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.clml.2026.05.012_bib0055","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1038\/leu.2016.113","article-title":"Effect of first-line treatment on second primary malignancies and Richter's transformation in patients with CLL","volume":"30","author":"Maurer","year":"2016","journal-title":"Leukemia"},{"issue":"6","key":"10.1016\/j.clml.2026.05.012_bib0056","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1200\/JCO.2008.17.5398","article-title":"Other malignancies in chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"27","author":"Tsimberidou","year":"2009","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.clml.2026.05.012_bib0057","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1002\/hon.3192","article-title":"A population level analysis of second hematological malignancies in chronic lymphocytic leukemia\/small lymphocytic lymphoma survivors in the era of targeted therapies","volume":"41","author":"Mishra","year":"2023","journal-title":"Hematol Oncol"},{"issue":"10","key":"10.1016\/j.clml.2026.05.012_bib0058","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1038\/leu.2016.113","article-title":"Effect of first-line treatment on second primary malignancies and Richter's transformation in patients with CLL","volume":"30","author":"Maurer","year":"2016","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.clml.2026.05.012_bib0059","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.hoc.2013.01.003","article-title":"Understanding the immunodeficiency in chronic lymphocytic leukemia: potential clinical implications","volume":"27","author":"Riches","year":"2013","journal-title":"Hematol Oncol Clin North Am"},{"issue":"15","key":"10.1016\/j.clml.2026.05.012_bib0060","doi-asserted-by":"crossref","first-page":"3856","DOI":"10.3390\/cancers13153856","article-title":"Impact of immune parameters and immune dysfunctions on the prognosis of patients with chronic lymphocytic leukemia","volume":"13","author":"Vitale","year":"2021","journal-title":"Cancers"},{"issue":"14","key":"10.1016\/j.clml.2026.05.012_bib0061","doi-asserted-by":"crossref","first-page":"2252","DOI":"10.1182\/blood.2021013926","article-title":"Single-cell analysis reveals immune dysfunction from the earliest stages of CLL that can be reversed by ibrutinib","volume":"139","author":"Purroy","year":"2022","journal-title":"Blood"},{"issue":"9581","key":"10.1016\/j.clml.2026.05.012_bib0062","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0140-6736(07)61050-2","article-title":"Incidence of cancers in people with HIV\/AIDS compared with immunosuppressed transplant recipients: a meta-analysis","volume":"370","author":"Grulich","year":"2007","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.clml.2026.05.012_bib0063","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1182\/hematology.2021000261","article-title":"How immunodeficiency can lead to malignancy","volume":"2021","author":"Pai","year":"2021","journal-title":"Hematol Am Soc Hematol Educ Program"},{"issue":"7","key":"10.1016\/j.clml.2026.05.012_bib0064","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1038\/s41409-025-02606-1","article-title":"Subsequent cancers following non-myeloablative conditioning for allogeneic hematopoietic cell transplantation","volume":"60","author":"Vo","year":"2025","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"10.1016\/j.clml.2026.05.012_bib0065","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1182\/blood-2012-09-457531","article-title":"T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production","volume":"121","author":"Riches","year":"2013","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.clml.2026.05.012_bib0066","doi-asserted-by":"crossref","first-page":"2012","DOI":"10.1038\/s41375-020-0873-2","article-title":"T-cells in chronic lymphocytic leukemia: guardians or drivers of disease?","volume":"34","author":"Roessner","year":"2020","journal-title":"Leukemia"},{"issue":"7","key":"10.1016\/j.clml.2026.05.012_bib0067","first-page":"2427","article-title":"Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug","volume":"118","author":"Ramsay","year":"2008","journal-title":"J Clin Invest"},{"issue":"7","key":"10.1016\/j.clml.2026.05.012_bib0068","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1182\/blood-2012-02-411678","article-title":"Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer","volume":"120","author":"Ramsay","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.05.012_bib0069","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.ejca.2016.11.020","article-title":"Major infections, secondary cancers and autoimmune diseases occur in different clinical subsets of chronic lymphocytic leukaemia patients","volume":"72","author":"Visentin","year":"2017","journal-title":"Eur J Cancer"},{"issue":"3","key":"10.1016\/j.clml.2026.05.012_bib0070","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/j.1365-2141.2007.06801.x","article-title":"Risk factors for development of a second lymphoid malignancy in patients with chronic lymphocytic leukaemia","volume":"139","author":"Maddocks-Christianson","year":"2007","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.clml.2026.05.012_bib0071","first-page":"2311","article-title":"Genetics of lymphocytes influences the emergence of second cancer in chronic lymphocytic leukemia","volume":"34","author":"Bernues","year":"2014","journal-title":"Anticancer Res"},{"issue":"5","key":"10.1016\/j.clml.2026.05.012_bib0072","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/ng.2584","article-title":"POT1 mutations cause telomere dysfunction in chronic lymphocytic leukemia","volume":"45","author":"Ramsay","year":"2013","journal-title":"Nat Genet"},{"issue":"4","key":"10.1016\/j.clml.2026.05.012_bib0073","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.70315","article-title":"Clinical, genetic, and familial features of POT1 tumor predisposition syndrome","volume":"132","author":"DiNardo","year":"2026","journal-title":"Cancer"},{"issue":"26","key":"10.1016\/j.clml.2026.05.012_bib0074","doi-asserted-by":"crossref","first-page":"2422","DOI":"10.1056\/NEJMoa2300503","article-title":"Familial clonal hematopoiesis in a long telomere syndrome","volume":"388","author":"DeBoy","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2026.05.012_bib0075","author":"Accardo","year":"2026","journal-title":"POT1 Tumor Predisposition. GeneReviews"},{"issue":"4","key":"10.1016\/j.clml.2026.05.012_bib0076","doi-asserted-by":"crossref","first-page":"904","DOI":"10.3324\/haematol.2024.286031","article-title":"Investigating the influence of germline ATM variants in chronic lymphocytic leukemia on cancer vulnerability","volume":"110","author":"Azevedo","year":"2025","journal-title":"Haematologica"},{"issue":"2","key":"10.1016\/j.clml.2026.05.012_bib0077","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1182\/blood-2005-12-5022","article-title":"Variants in the ATM-BRCA2-CHEK2 axis predispose to chronic lymphocytic leukemia","volume":"108","author":"Rudd","year":"2006","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2026.05.012_bib0078","doi-asserted-by":"crossref","first-page":"E432","DOI":"10.1002\/ijc.29237","article-title":"Relationship between ambient ultraviolet radiation and non-Hodgkin lymphoma subtypes: a U.S. population-based study of racial and ethnic groups","volume":"136","author":"Cahoon","year":"2015","journal-title":"Int J Cancer"},{"issue":"4","key":"10.1016\/j.clml.2026.05.012_bib0079","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1158\/1055-9965.EPI-04-0693","article-title":"Cigarette smoking and risk of non-Hodgkin Lymphoma: a pooled analysis from the International Lymphoma Epidemiology Consortium (InterLymph)","volume":"14","author":"Morton","year":"2005","journal-title":"Cancer Epidemiol Biomark Prev"},{"issue":"12","key":"10.1016\/j.clml.2026.05.012_bib0080","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1182\/blood.2025029905","article-title":"The landscape and evolution of clonal hematopoiesis in chronic lymphocytic leukemia","volume":"147","author":"Al-Sawaf","year":"2026","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2026.05.012_bib0081","doi-asserted-by":"crossref","DOI":"10.1002\/hem3.70322","article-title":"Dissecting clonal hematopoiesis in the myeloid compartment of chronic lymphocytic leukemia and Richter transformation","volume":"10","author":"Cosentino","year":"2026","journal-title":"Hemasphere"},{"issue":"23","key":"10.1016\/j.clml.2026.05.012_bib0082","doi-asserted-by":"crossref","first-page":"5949","DOI":"10.1182\/bloodadvances.2024013414","article-title":"Myeloid clonal hematopoiesis of indeterminate potential in patients with chronic lymphocytic leukemia","volume":"8","author":"Vijenthira","year":"2024","journal-title":"Blood Adv"},{"issue":"3","key":"10.1016\/j.clml.2026.05.012_bib0083","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.70633","article-title":"Clonal haematopoiesis in chronic lymphocytic leukaemia: biology, inflammaging and clinical implications in the era of targeted therapy","volume":"16","author":"Martino","year":"2026","journal-title":"Clin Transl Med"},{"issue":"20","key":"10.1016\/j.clml.2026.05.012_bib0084","doi-asserted-by":"crossref","first-page":"1996","DOI":"10.1016\/j.jacc.2023.03.401","article-title":"Clonal hematopoiesis of indeterminate potential predicts adverse outcomes in patients with atherosclerotic cardiovascular disease","volume":"81","author":"Gumuser","year":"2023","journal-title":"J Am Coll Cardiol"},{"issue":"26","key":"10.1016\/j.clml.2026.05.012_bib0085","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"Jaiswal","year":"2014","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.clml.2026.05.012_bib0086","doi-asserted-by":"crossref","first-page":"3104","DOI":"10.1080\/10428194.2019.1665669","article-title":"Chronic lymphocytic leukemia, skin and other second cancers","volume":"60","author":"Mulligan","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1016\/j.clml.2026.05.012_bib0087","doi-asserted-by":"crossref","DOI":"10.57264\/cer-2023-0119","article-title":"Assessment of second primary malignancies among treated and untreated patients with chronic lymphocytic leukemia using real-world data from the USA","volume":"13","author":"Ailawadhi","year":"2024","journal-title":"J Comp Eff Res"},{"issue":"12","key":"10.1016\/j.clml.2026.05.012_bib0088","doi-asserted-by":"crossref","first-page":"E457","DOI":"10.1002\/ajh.26363","article-title":"Second primary malignancies in treated and untreated patients with chronic lymphocytic leukemia","volume":"96","author":"Furstenau","year":"2021","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.clml.2026.05.012_bib0089","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/bjh.17337","article-title":"Risk of new malignancies among patients with CLL treated with chemotherapy: results of a Danish population-based study","volume":"193","author":"da Cunha-Bang","year":"2021","journal-title":"Br J Haematol"},{"issue":"5","key":"10.1016\/j.clml.2026.05.012_bib0090","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1038\/bjc.2013.381","article-title":"Increased risk of second malignancies in chronic lymphocytic leukaemia patients as compared with follicular lymphoma patients: a Canadian population-based study","volume":"109","author":"Beiggi","year":"2013","journal-title":"Br J Cancer"},{"issue":"8","key":"10.1016\/j.clml.2026.05.012_bib0091","doi-asserted-by":"crossref","first-page":"3052","DOI":"10.1172\/JCI89756","article-title":"Ibrutinib treatment improves T cell number and function in CLL patients","volume":"127","author":"Long","year":"2017","journal-title":"J Clin Invest"},{"key":"10.1016\/j.clml.2026.05.012_bib0092","article-title":"Ibrutinib-based therapy reinvigorates CD8+ T cells compared to chemoimmunotherapy: immune-monitoring from the E1912 trial","author":"Papazoglou","year":"2023","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.05.012_bib0093","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1182\/blood-2020-140042","article-title":"Risk of secondary malignancy in CLL patients treated with novel targeted agents","volume":"136","author":"Eversman","year":"2020","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2026.05.012_bib0094","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1038\/s41375-021-01485-x","article-title":"Efficacy and safety in a 4-year follow-up of the ELEVATE-TN study comparing acalabrutinib with or without obinutuzumab versus obinutuzumab plus chlorambucil in treatment-na\u00efve chronic lymphocytic leukemia","volume":"36","author":"Sharman","year":"2022","journal-title":"Leukemia"},{"issue":"10232","key":"10.1016\/j.clml.2026.05.012_bib0095","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/S0140-6736(20)30262-2","article-title":"Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial","volume":"395","author":"Sharman","year":"2020","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.clml.2026.05.012_bib0096","doi-asserted-by":"crossref","first-page":"2849","DOI":"10.1200\/JCO.19.03355","article-title":"ASCEND: phase III, randomized trial of Acalabrutinib versus Idelalisib plus Rituximab or Bendamustine Plus Rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"38","author":"Ghia","year":"2020","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.clml.2026.05.012_bib0097","doi-asserted-by":"crossref","DOI":"10.1097\/HS9.0000000000000801","article-title":"Acalabrutinib versus investigator's choice in relapsed\/refractory chronic lymphocytic leukemia: final ASCEND trial results","volume":"6","author":"Ghia","year":"2022","journal-title":"Hemasphere"},{"issue":"1","key":"10.1016\/j.clml.2026.05.012_bib0098","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1002\/jha2.146","article-title":"Acalabrutinib-related second primary malignancies and nonmelanoma skin cancers in patients with chronic lymphocytic leukaemia (CLL): a systematic review and meta-analysis of randomised controlled trials (RCTs)","volume":"2","author":"Htut","year":"2021","journal-title":"EJHaem"},{"issue":"3","key":"10.1016\/j.clml.2026.05.012_bib0099","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1111\/j.1365-2141.2005.05550.x","article-title":"Diagnostic criteria for monoclonal B-cell lymphocytosis","volume":"130","author":"Marti","year":"2005","journal-title":"Br J Haematol"},{"issue":"4","key":"10.1016\/j.clml.2026.05.012_bib0100","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1182\/blood-2015-02-585059","article-title":"Monoclonal B-cell lymphocytosis and early-stage chronic lymphocytic leukemia: diagnosis, natural history, and risk stratification","volume":"126","author":"Strati","year":"2015","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2026.05.012_bib0101","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/s41375-020-0799-8","article-title":"Risk of serious infection among individuals with and without low count monoclonal B-cell lymphocytosis (MBL)","volume":"35","author":"Shanafelt","year":"2021","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.clml.2026.05.012_bib0102","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/leu.2012.187","article-title":"Infectious complications among individuals with clinical monoclonal B-cell lymphocytosis (MBL): a cohort study of newly diagnosed cases compared to controls","volume":"27","author":"Moreira","year":"2013","journal-title":"Leukemia"},{"issue":"2","key":"10.1016\/j.clml.2026.05.012_bib0103","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/leu.2015.235","article-title":"Risk of non-hematologic cancer in individuals with high-count monoclonal B-cell lymphocytosis","volume":"30","author":"Solomon","year":"2016","journal-title":"Leukemia"},{"issue":"15","key":"10.1016\/j.clml.2026.05.012_bib0104","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1182\/blood.2022016279","article-title":"Progression and survival of MBL: a screening study of 10\u2009139 individuals","volume":"140","author":"Slager","year":"2022","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.clml.2026.05.012_bib0105","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1200\/JCO.23.02738","article-title":"Chronic lymphocytic leukemia: time to care for the survivors","volume":"42","author":"Fedele","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clml.2026.05.012_bib0106","unstructured":"Brumble R Nurses note: the importance of screening for secondary cancers after being diagnosed with CLL or SLL. Available at: https:\/\/cllsociety.org\/2023\/04\/nurses-note-importance-of-screening\/. Accessed: October 12, 2024."},{"issue":"3","key":"10.1016\/j.clml.2026.05.012_bib0107","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1586\/17474086.2016.1129893","article-title":"A review of supportive care and recommended preventive approaches for patients with chronic lymphocytic leukemia","volume":"9","author":"Randhawa","year":"2016","journal-title":"Expert Rev Hematol"},{"issue":"3","key":"10.1016\/j.clml.2026.05.012_bib0108","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1080\/10428194.2017.1349903","article-title":"Recommendations for skin cancer monitoring for patients with chronic lymphocytic leukemia","volume":"59","author":"Mulcahy","year":"2018","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"10.1016\/j.clml.2026.05.012_bib0109","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1200\/JOP.2013.000921","article-title":"Skin cancer surveillance and malignancies of the skin in a community-dwelling cohort of patients with newly diagnosed chronic lymphocytic leukemia","volume":"10","author":"Mansfield","year":"2014","journal-title":"J Oncol Pract"},{"issue":"13","key":"10.1016\/j.clml.2026.05.012_bib0110","doi-asserted-by":"crossref","first-page":"3204","DOI":"10.1080\/10428194.2019.1620941","article-title":"Risk factors for skin cancer and solid tumors in newly diagnosed patients with chronic lymphocytic leukemia and the impact of skin surveillance on survival","volume":"60","author":"Ishdorj","year":"2019","journal-title":"Leuk Lymphoma"},{"issue":"Supplement 1","key":"10.1016\/j.clml.2026.05.012_bib0111","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1182\/blood-2025-517","article-title":"Longitudinal trends in vaccination and cancer screening engagement among patients with chronic lymphocytic leukemia: a prospective cohort study and quality improvement initiative (2019\u20132025)","volume":"146","author":"Bharathi","year":"2025","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2026.05.012_bib0112","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/j.hoc.2021.03.010","article-title":"Can immunocompetence be restored in chronic lymphocytic leukemia?","volume":"35","author":"Sun","year":"2021","journal-title":"Hematol Oncol Clin North Am"},{"issue":"10","key":"10.1016\/j.clml.2026.05.012_bib0113","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0258423","article-title":"Detailing the epidemiological and clinical characteristics of chronic lymphocytic leukaemia in Portugal-results from a population-based cancer registry cohort study","volume":"16","author":"Cardoso Borges","year":"2021","journal-title":"PLoS One"},{"issue":"25","key":"10.1016\/j.clml.2026.05.012_bib0114","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1056\/NEJMoa1509388","article-title":"Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia","volume":"373","author":"Burger","year":"2015","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.clml.2026.05.012_bib0115","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.1182\/blood.2024028205","article-title":"Final analysis of the RESONATE-2 study: up to 10 years of follow-up of first-line ibrutinib treatment for CLL\/SLL","volume":"146","author":"Burger","year":"2025","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.clml.2026.05.012_bib0116","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib regimens versus chemoimmunotherapy in older patients with untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.clml.2026.05.012_bib0117","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1182\/blood.2021010845","article-title":"The CLL12 trial: ibrutinib vs placebo in treatment-na\u00efve, early-stage chronic lymphocytic leukemia","volume":"139","author":"Langerbeins","year":"2022","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.clml.2026.05.012_bib0118","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1182\/blood.2021014960","article-title":"Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial","volume":"140","author":"Shanafelt","year":"2022","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.clml.2026.05.012_bib0119","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1056\/NEJMoa1817073","article-title":"Ibrutinib\u2013Rituximab or chemoimmunotherapy for chronic lymphocytic leukemia","volume":"381","author":"Shanafelt","year":"2019","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.clml.2026.05.012_bib0120","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S1470-2045(23)00144-4","article-title":"Ibrutinib and rituximab versus fludarabine, cyclophosphamide, and rituximab for patients with previously untreated chronic lymphocytic leukaemia (FLAIR): interim analysis of a multicentre, open-label, randomised, phase 3 trial","volume":"24","author":"Hillmen","year":"2023","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.clml.2026.05.012_bib0121","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1056\/NEJMoa2504341","article-title":"Measurable residual disease-guided therapy for chronic lymphocytic leukemia","volume":"393","author":"Munir","year":"2025","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.clml.2026.05.012_bib0122","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(18)30788-5","article-title":"Ibrutinib plus obinutuzumab versus chlorambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial","volume":"20","author":"Moreno","year":"2019","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.clml.2026.05.012_bib0123","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1182\/blood.2024024476","article-title":"Acalabrutinib-obinutuzumab improves survival vs chemoimmunotherapy in treatment-naive CLL in the 6-year follow-up of ELEVATE-TN","volume":"146","author":"Sharman","year":"2025","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.clml.2026.05.012_bib0124","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/S1470-2045(22)00293-5","article-title":"Zanubrutinib versus bendamustine and rituximab in untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (SEQUOIA): a randomised, controlled, phase 3 trial","volume":"23","author":"Tam","year":"2022","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.clml.2026.05.012_bib0125","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1200\/JCO-24-02265","article-title":"Zanubrutinib versus Bendamustine and Rituximab in patients with treatment-na\u00efve chronic lymphocytic leukemia\/small lymphocytic lymphoma: median 5-year follow-up of SEQUOIA","volume":"43","author":"Shadman","year":"2025","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.clml.2026.05.012_bib0126","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S1470-2045(23)00452-7","article-title":"Fixed-duration ibrutinib-venetoclax versus chlorambucil-obinutuzumab in previously untreated chronic lymphocytic leukaemia (GLOW): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial","volume":"24","author":"Niemann","year":"2023","journal-title":"Lancet Oncol"},{"issue":"23","key":"10.1016\/j.clml.2026.05.012_bib0127","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1815281","article-title":"Venetoclax and Obinutuzumab in patients with CLL and coexisting conditions","volume":"380","author":"Fischer","year":"2019","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.clml.2026.05.012_bib0128","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1016\/S1470-2045(20)30443-5","article-title":"Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): follow-up results from a multicentre, open-label, randomised, phase 3 trial","volume":"21","author":"Al-Sawaf","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2026.05.012_bib0129","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2024024631","article-title":"Venetoclax-Obinutuzumab for previously untreated chronic lymphocytic leukemia: 6-year results of the phase 3 CLL14 study","author":"Al-Sawaf","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.clml.2026.05.012_bib0130","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1038\/s41467-023-37648-w","article-title":"Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia","volume":"14","author":"Al-Sawaf","year":"2023","journal-title":"Nat Commun"},{"issue":"19","key":"10.1016\/j.clml.2026.05.012_bib0131","doi-asserted-by":"crossref","first-page":"1739","DOI":"10.1056\/NEJMoa2213093","article-title":"First-line venetoclax combinations in chronic lymphocytic leukemia","volume":"388","author":"Eichhorst","year":"2023","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.clml.2026.05.012_bib0132","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1016\/S1470-2045(24)00196-7","article-title":"First-line venetoclax combinations versus chemoimmunotherapy in fit patients with chronic lymphocytic leukaemia (GAIA\/CLL13): 4-year follow-up from a multicentre, open-label, randomised, phase 3 trial","volume":"25","author":"F\u00fcrstenau","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2026.05.012_bib0133","article-title":"Fixed-duration versus continuous treatment for chronic lymphocytic leukemia","author":"Al-Sawaf","year":"2025","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.clml.2026.05.012_bib0134","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1400376","article-title":"Ibrutinib versus Ofatumumab in previously treated chronic lymphoid leukemia","volume":"371","author":"Byrd","year":"2014","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.clml.2026.05.012_bib0135","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/S1470-2045(15)00465-9","article-title":"Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study","volume":"17","author":"Chanan-Khan","year":"2016","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.clml.2026.05.012_bib0136","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1038\/s41375-018-0276-9","article-title":"Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"33","author":"Fraser","year":"2019","journal-title":"Leukemia"},{"issue":"13","key":"10.1016\/j.clml.2026.05.012_bib0137","doi-asserted-by":"crossref","first-page":"3188","DOI":"10.1080\/10428194.2020.1795159","article-title":"Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed\/refractory chronic lymphocytic leukemia\/small lymphocytic lymphoma","volume":"61","author":"Fraser","year":"2020","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"10.1016\/j.clml.2026.05.012_bib0138","doi-asserted-by":"crossref","first-page":"e254","DOI":"10.1016\/S2352-3026(20)30433-6","article-title":"Ublituximab plus ibrutinib versus ibrutinib alone for patients with relapsed or refractory high-risk chronic lymphocytic leukaemia (GENUINE): a phase 3, multicentre, open-label, randomised trial","volume":"8","author":"Sharman","year":"2021","journal-title":"e Lancet Haematol"},{"issue":"31","key":"10.1016\/j.clml.2026.05.012_bib0139","doi-asserted-by":"crossref","first-page":"3441","DOI":"10.1200\/JCO.21.01210","article-title":"Acalabrutinib versus Ibrutinib in previously treated chronic lymphocytic leukemia: results of the first randomized phase III trial","volume":"39","author":"Byrd","year":"2021","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.clml.2026.05.012_bib0140","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1056\/NEJMoa2211582","article-title":"Zanubrutinib or ibrutinib in relapsed or refractory chronic lymphocytic leukemia","volume":"388","author":"Brown","year":"2023","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.clml.2026.05.012_bib0141","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax\u2013Rituximab in relapsed or refractory chronic lymphocytic leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N Engl J Med"},{"issue":"34","key":"10.1016\/j.clml.2026.05.012_bib0142","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1200\/JCO.20.00948","article-title":"Venetoclax plus Rituximab in relapsed chronic lymphocytic leukemia: 4-year results and evaluation of impact of genomic complexity and gene mutations from the MURANO Phase III study","volume":"38","author":"Kater","year":"2020","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.1016\/j.clml.2026.05.012_bib0143","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1182\/blood.2021015014","article-title":"Enduring undetectable MRD and updated outcomes in relapsed\/refractory CLL after fixed-duration venetoclax-rituximab","volume":"140","author":"Seymour","year":"2022","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.clml.2026.05.012_bib0144","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S1470-2045(24)00070-6","article-title":"Activity of venetoclax in patients with relapsed or refractory chronic lymphocytic leukaemia: analysis of the VENICE-1 multicentre, open-label, single-arm, phase 3b trial","volume":"25","author":"Kater","year":"2024","journal-title":"Lancet Oncol"},{"issue":"22","key":"10.1016\/j.clml.2026.05.012_bib0145","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1200\/JCO-25-00166","article-title":"Phase III trial of Pirtobrutinib versus Idelalisib\/Rituximab or Bendamustine\/Rituximab in covalent bruton tyrosine kinase inhibitor\u2013Pretreated chronic lymphocytic leukemia\/small lymphocytic lymphoma (BRUIN CLL-321)","volume":"43","author":"Sharman","year":"2025","journal-title":"J Clin Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026001655?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026001655?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T19:48:37Z","timestamp":1787860117000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265026001655"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":145,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2152265026001655"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2026.05.012","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Second Primary Malignancies in Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma: A Comprehensive Review","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2026.05.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}